SCHEMBL4038122

SCHEMBL4038122

O=C(O)c1cc(CNc2ccccc2C(=O)Nc2cccc(C(F)(F)F)c2)ccn1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT1 P17948 2/20 0.75
▸ KDR P35968 2/20 0.75
▸ KIT P10721 2/20 0.75
▸ ABL1 P00519 1/20 0.75
▸ EGFR P00533 1/20 0.75
▸ CSF1R P07333 1/20 0.75
▸ PDGFRB P09619 1/20 0.75
▸ FLT4 P35916 1/20 0.75
▸ RXFP1 Q9HBX9 16/20 0.74
▸ RXFP2 Q8WXD0 1/20 0.56
▸ MEN1 O00255 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ HPGD P15428 1/20 0.55
▸ HTT P42858 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ BRAF P15056 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2489551 0.88 ABL1 (0.78) FLT1KDRKITABL1EGFR
SCHEMBL3866257 0.87 KIT (0.76) FLT1KDRKITABL1EGFR
SCHEMBL3865996 0.87 ABL1 (0.76) FLT1KDRKITABL1EGFR
SCHEMBL27627634 0.87 KIT (0.67) FLT1KDRKITABL1EGFR
SCHEMBL4038127 0.86 ABL1 (0.71) FLT1KDRKITABL1EGFR
SCHEMBL29356168 0.86 KDR (1.00) FLT1KDRKITABL1EGFR
SCHEMBL4976103 0.86 KDR (1.00) FLT1KDRKITABL1EGFR
SCHEMBL15529379 0.86 RXFP1 (1.00) FLT1KDRKITABL1EGFR
SCHEMBL15528722 0.86 RXFP1 (1.00) FLT1KDRKITABL1EGFR
SCHEMBL5900627 0.85 ABL1 (0.72) FLT1KDRKITABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392680-B1 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 BAYER SCHERING PHARMA AG (DE) 2009-07-22 — — EP disclosed
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-16 — — US disclosed
EP-1392680-A2 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 SCHERING AKTIENGESELLSCHAFT (DE) 2004-03-03 — — EP disclosed
WO-2002090352-A2 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 SCHERING AKTIENGESELLSCHAFT (DE) 2002-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 FLT4, KDR, FLT1 FLT1 3/4885KDR 2/4885KIT 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback